An analysis finds distinct adverse event reporting patterns across immunosuppressive regimens, highlighting the need for tailored safety monitoring.
|Articles|August 29, 2012
Companies Expanding Their Services Through Ventures with ACOs
Advertisement
Whether it is through contracted services, formal and informational discussions, or joint operating committees, post-acute providers are finding different ways to offer their services to the quickly expanding roster of accountable care organizations.
Read the full story:
Source: ModernHealthcare.com
And while the transition toward integrated care—and a new payment model that rewards for it—has everyone re-thinking how they deliver care, many post-acute providers say their work with ACOs is a natural progression for their businesses.
Advertisement
Related to this article
On National Latinx AIDS Awareness Day, experts outline HIV prevention gaps in Hispanic communities and how payers can ease PrEP access.
HR 1 brings Medicaid work requirements and narrower immigrant eligibility by January 2027, and CBO projects 10 million more uninsured by 2034.
CMS ends ACA subsidies for 189,000 enrollees with duplicate Medicare, Medicaid, or CHIP coverage or listed as deceased, with a 30-day dispute window.
Subcutaneous mosunetuzumab plus polatuzumab vedotin boosts responses in relapsed large B-cell lymphoma, helping community oncology care.
Using baseline samples from 177 patients in the VISION/HO141 trial, researchers built a functional prognostic model for CLL that outperformed the CLL-IPI.
The Franklin County death is under state review as Pennsylvania's measles outbreak passed 1100 cases and 219 hospitalizations.
Among 4378 Spanish registry patients, dyshidrotic eczema was less tied to occupation than other hand eczema.
Advertisement
Advertisement
Trending on AJMC
1
Coroner Reports Pennsylvania's Sixth Measles-Associated Death
2
ACA Subsidies End for 189,000 Duplicate or Deceased Enrollees
3
5 Things to Know About the One Big Beautiful Bill Act
4
Understanding the Potential Risks of Prescription Drug Affordability Boards and Upper Payment Limits
5